ArticleTranslational cancer research2026
Identification of prognostic risk factors and construction of nomograms for elderly patients with stage III-IV endometrioid endometrial carcinoma: a study based on the SEER database.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The incidence of endometrial cancer among elderly women has been increasing year by year, and endometrioid endometrial carcinoma (EC) is the predominant histological subtype of endometrial cancer. Unfortunately, elderly patients with advanced-stage endometrioid EC continue to experience unfavorable prognostic outcomes. To date, reliable instruments for individualized prognosis estimation among elderly patients with stage III-IV endometrioid EC are still lacking. Therefore, this investigation sought to determine prognostic indicators and develop nomograms for the prediction of overall survival (OS) and cancer-specific survival (CSS) in this patient population. Methods: This study utilized data from the Surveillance, Epidemiology, and End Results (SEER) database, analyzing eligible elderly patients (aged ≥60 years) with stage III-IV endometrioid EC. The Kaplan-Meier approach was employed for survival analysis, while univariate and multivariate Cox regression analyses were used to identify factors independently associated with prognosis. Based on these characteristics, nomograms were constructed and subsequently evaluated via receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA) to assess their discriminative performance, model fit, and potential clinical utility. Results: Multivariable Cox proportional hazards regression showed that age, tumor grade, N stage, chemotherapy, radiotherapy, surgery, and brain metastasis were independently linked to OS as well as CSS. The nomograms incorporating these variables demonstrated good predictive performance in both the training and validation cohorts. The calculated area under the curve (AUC) for OS ranged from 0.76 to 0.88, while those for CSS ranged from 0.77 to 0.84. Calibration curves demonstrated excellent agreement between the predicted and observed survival probabilities. Moreover, DCA indicated that the nomograms provided favorable net clinical benefits across a broad range of threshold probabilities. Conclusions: The constructed nomograms demonstrated satisfactory performance in predicting survival outcomes among elderly patients with advanced endometrioid EC, with good discriminatory ability. These models may facilitate individualized risk stratification, although further external validation is warranted before routine clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.